Table 3.
Frequency of serious adverse events according treatment status from 2015 to 2019
| Events | Cohorts | |
|---|---|---|
| GLP-1RA (N = 20,762) N (%) | SGLT-2i (N = 20,762) N (%) | |
| Hypoglycemia | 11 (0.05) | 1 (0.00) |
| Ketoacidosis | 14 (0.07) | 18 (0.09) |
| Diabetic coma | 5 (0.02) | 7 (0.03) |
| Acute kidney failure | 12 (0.06) | 2 (0.01) |
| Syncope | 70 (0.34) | 72 (0.35) |
| Fractures | 241 (1.16) | 243 (1.17) |
| Amputations | 53 (0.26) | 67 (0.32) |
GLP-1RA glucagon-like peptide-1 receptor agonists, SGLT-2i sodium glucose transporter-2 inhibitors;
MACE-3 all cause death, non-fatal myocardial infarction, non-fatal stroke, MACE-4 all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina